“Based on clinical data, peramivir is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza,” Rich Whitley, a professor at the University of Alabama at Birmingham and the presenting author of the study, said.
